RU2014125071A - Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa - Google Patents
Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa Download PDFInfo
- Publication number
- RU2014125071A RU2014125071A RU2014125071/10A RU2014125071A RU2014125071A RU 2014125071 A RU2014125071 A RU 2014125071A RU 2014125071/10 A RU2014125071/10 A RU 2014125071/10A RU 2014125071 A RU2014125071 A RU 2014125071A RU 2014125071 A RU2014125071 A RU 2014125071A
- Authority
- RU
- Russia
- Prior art keywords
- allele
- patient
- response
- seq
- group
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title claims abstract 27
- 238000000034 method Methods 0.000 title claims abstract 27
- 239000005557 antagonist Substances 0.000 title claims abstract 20
- 201000001263 Psoriatic Arthritis Diseases 0.000 title claims abstract 16
- 208000036824 Psoriatic arthropathy Diseases 0.000 title claims abstract 16
- 108700028369 Alleles Proteins 0.000 claims abstract 67
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims abstract 17
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims abstract 17
- 239000012472 biological sample Substances 0.000 claims abstract 16
- 238000004458 analytical method Methods 0.000 claims abstract 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims abstract 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 2
- 239000003246 corticosteroid Substances 0.000 claims abstract 2
- 229960000485 methotrexate Drugs 0.000 claims abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract 2
- 108020004707 nucleic acids Proteins 0.000 claims abstract 2
- 102000039446 nucleic acids Human genes 0.000 claims abstract 2
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims abstract 2
- 229960001940 sulfasalazine Drugs 0.000 claims abstract 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims abstract 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 9
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 238000010240 RT-PCR analysis Methods 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 1
- 108010052199 HLA-C Antigens Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 229960004540 secukinumab Drugs 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rehabilitation Therapy (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IQ370/2011 | 2011-11-21 | ||
| IQ3702011 | 2011-11-21 | ||
| US201261624564P | 2012-04-16 | 2012-04-16 | |
| US61/624,564 | 2012-04-16 | ||
| PCT/US2012/041310 WO2013077907A1 (en) | 2011-11-21 | 2012-06-07 | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014125071A true RU2014125071A (ru) | 2015-12-27 |
Family
ID=48470189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014125071/10A RU2014125071A (ru) | 2011-11-21 | 2012-06-07 | Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150064193A1 (enExample) |
| EP (1) | EP2783014A1 (enExample) |
| JP (1) | JP2015504430A (enExample) |
| KR (1) | KR20140097178A (enExample) |
| CN (1) | CN104011223A (enExample) |
| AR (1) | AR086907A1 (enExample) |
| AU (1) | AU2012341081B2 (enExample) |
| BR (1) | BR112014012101A2 (enExample) |
| CA (1) | CA2856252A1 (enExample) |
| MX (1) | MX2014006158A (enExample) |
| RU (1) | RU2014125071A (enExample) |
| WO (1) | WO2013077907A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SI3757126T1 (sl) | 2010-11-05 | 2025-12-31 | Novartis Ag | Postopki za zdravljenje psoriatičnega artritisa z antagonisti il-17 |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3682905T3 (pl) | 2011-10-03 | 2022-04-04 | Modernatx, Inc. | Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania |
| PL2791160T3 (pl) | 2011-12-16 | 2022-06-20 | Modernatx, Inc. | Kompozycje zmodyfikowanego mrna |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| JP2017521479A (ja) | 2014-05-15 | 2017-08-03 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| JP2017528465A (ja) * | 2014-09-10 | 2017-09-28 | ノバルティス アーゲー | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用 |
| AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2016118921A1 (en) * | 2015-01-24 | 2016-07-28 | Abbvie, Inc. | Compositions and methods for treating psoriatic arthritis |
| JP6931648B2 (ja) | 2015-10-27 | 2021-09-08 | ユーシービー バイオファルマ エスアールエル | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 |
| IL283192B2 (en) * | 2018-11-20 | 2025-10-01 | Janssen Biotech Inc | A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody |
| AU2020288749A1 (en) * | 2019-06-04 | 2022-02-03 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody |
| CN114981302A (zh) * | 2019-09-20 | 2022-08-30 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗自身免疫性疾病的方法 |
| EP4305062A1 (en) * | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
| CA3212729A1 (en) * | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
| CN114427001A (zh) * | 2022-01-29 | 2022-05-03 | 中日友好医院(中日友好临床医学研究所) | 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| PL1963368T6 (pl) | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US20100239590A1 (en) * | 2007-06-20 | 2010-09-23 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| JP5581323B2 (ja) | 2008-09-29 | 2014-08-27 | ロシュ グリクアート アクチェンゲゼルシャフト | ヒトｉｌ１７に対する抗体およびその使用 |
| IN2012DN00767A (enExample) * | 2009-07-28 | 2015-06-26 | Janssen Biotech Inc | |
| EP2625199B1 (en) * | 2010-10-08 | 2017-11-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
-
2012
- 2012-06-07 RU RU2014125071/10A patent/RU2014125071A/ru not_active Application Discontinuation
- 2012-06-07 JP JP2014542299A patent/JP2015504430A/ja active Pending
- 2012-06-07 MX MX2014006158A patent/MX2014006158A/es unknown
- 2012-06-07 KR KR1020147013196A patent/KR20140097178A/ko not_active Withdrawn
- 2012-06-07 BR BR112014012101A patent/BR112014012101A2/pt not_active IP Right Cessation
- 2012-06-07 EP EP12727081.7A patent/EP2783014A1/en not_active Withdrawn
- 2012-06-07 US US14/358,504 patent/US20150064193A1/en not_active Abandoned
- 2012-06-07 CN CN201280057295.5A patent/CN104011223A/zh active Pending
- 2012-06-07 AU AU2012341081A patent/AU2012341081B2/en not_active Ceased
- 2012-06-07 CA CA2856252A patent/CA2856252A1/en not_active Abandoned
- 2012-06-07 WO PCT/US2012/041310 patent/WO2013077907A1/en not_active Ceased
- 2012-06-11 AR ARP120102076A patent/AR086907A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012341081B2 (en) | 2015-06-04 |
| WO2013077907A1 (en) | 2013-05-30 |
| AU2012341081A1 (en) | 2014-05-29 |
| AR086907A1 (es) | 2014-01-29 |
| JP2015504430A (ja) | 2015-02-12 |
| KR20140097178A (ko) | 2014-08-06 |
| CA2856252A1 (en) | 2013-05-30 |
| MX2014006158A (es) | 2014-06-19 |
| BR112014012101A2 (pt) | 2019-09-24 |
| EP2783014A1 (en) | 2014-10-01 |
| CN104011223A (zh) | 2014-08-27 |
| US20150064193A1 (en) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014125071A (ru) | Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa | |
| JP2015504430A5 (enExample) | ||
| RU2014146594A (ru) | Способы лечения анкилозирующего спондилита с использованием антагонистов il-17 | |
| US12269873B2 (en) | Signature of TL1A (TNFSF15) signaling pathway | |
| EP2773773B1 (en) | T-cell receptor clonotypes shared among ankylosing spondylitis patients | |
| RU2016144177A (ru) | Способы избирательного лечения астмы с использованием антагонистов il-13 | |
| JP2017513937A5 (enExample) | ||
| KR20090088931A (ko) | 인터페론 알파 유도성 약력학적 마커 | |
| JP2017519498A5 (enExample) | ||
| CN102808030B (zh) | 单核苷多态性rs3888188在检测结核病易感性中的应用 | |
| Bojarojc-Nosowicz et al. | Polymorphism and expression of the tumour necrosis factor-alpha (TNF-alpha) gene in non-infected cows and in cows naturally infected with the bovine leukaemia virus (BLV). | |
| CN108823296A (zh) | 一种检测核酸样本污染的方法、试剂盒及应用 | |
| US20100092468A1 (en) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents | |
| CN102770140A (zh) | 治疗癌症的方法 | |
| EP3669004A1 (en) | Compositions and methods for treatment of atopic dermatitis and treatment selection | |
| CN112941164A (zh) | 利用目标基因测序检测trpc6基因致病突变的方法 | |
| WO2013107005A1 (zh) | 人稀有血型的多重pcr检测方法和试剂盒 | |
| JP2019520355A5 (enExample) | ||
| WO2022221605A2 (en) | Detection of sars-cov-2 variant | |
| KR102576154B1 (ko) | 습관성 유산 예측용 바이오마커 | |
| Jiao et al. | Gene analysis of two cases with CisAB/B blood subgroup | |
| KR20220061425A (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 | |
| KR20180019125A (ko) | 원발성 초점성 분절성 사구체경화증을 치료하는 방법 | |
| CA2547033A1 (en) | Ntrk1 genetic markers associated with progression of alzheimer's disease | |
| KR102126895B1 (ko) | 고밀도지질단백질콜레스테롤 수준을 예측하기 위한 조성물, 키트, 및 이를 이용한 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161110 |